Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
NA
370 participants
INTERVENTIONAL
2023-11-28
2034-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection
NCT02380716
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
NCT06827990
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
NCT02777593
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1
NCT02777528
Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
NCT00590759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ASG device only in Ascending Aorta
Ascending Aortic Isolated Lesions, Pseudoaneurysms and Penetrating Aortic Ulcers in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG device alone.
GORE® Ascending Stent Graft (ASG device)
Endovascular aortic repair of the ascending aorta
ASG + TBE
Ascending Aorta/Aortic Arch Isolated Lesions and Chronic De Novo Dissections in subjects at high-risk for surgical repair, treated with endovascular repair using the ASG and TBE devices.
GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)
Endovascular aortic repair of the ascending aorta/aortic arch
Surgical Follow-up Cohort
Open surgical repair of ascending aorta in subjects at high-risk for surgical repair
Surgery
Open surgical repair of the ascending aorta and/or the aortic arch
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GORE® Ascending Stent Graft (ASG device)
Endovascular aortic repair of the ascending aorta
GORE® Thoracic Aortic Graft Thoracic Branch Endoprosthesis (TBE Device)
Endovascular aortic repair of the ascending aorta/aortic arch
Surgery
Open surgical repair of the ascending aorta and/or the aortic arch
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Ascending Aortic pathologies warranting surgical repair compatible with the treatment requirements of the ASG device meeting any of the following criteria: Aneurysm
1. Fusiform aneurysm (≥50mm or documented growth rate \>0.5cm/year)
2. Saccular aneurysm (no diameter criteria)
3. Pseudoaneurysms (\>30 days post-surgery, no diameter criteria) Non-aneurysm
4. Penetrating Aortic Ulcers (PAUs) (no diameter criteria)
5. Pseudoaneurysms, following open surgical repair of a Type A dissection (\>30 days post-surgery, no diameter criteria)
2. Anatomic compatibility with ASG device based on Gore Imaging Sciences review.
1. Treatment must be limited to the ascending aorta
2. Lesion location is ≥2cm distal to the most distal coronary artery ostia
3. Distal extent of the lesion is located ≥2cm proximal to the origin of the Brachiocephalic Artery (BCA)
4. Proximal and distal landing zones must be ≥2cm in length
5. Landing zones cannot be heavily calcified, or heavily thrombosed
6. Landing zone diameter between 27mm - 48mm
7. For patients with prior replacement of the ascending aorta and/or aortic arch by an endovascular or surgical graft, there must be at least ≥2 cm overlap of ASG device and previously implanted graft.
3. Considered high-risk for open surgical repair by meeting any of the following criteria:
1. ≥75 years of age
2. Previous median sternotomy
3. Documented identification of other subject-specific risk factors (e.g., medical history, active medical diagnosis) by a study investigator and an experienced open ascending and/or aortic arch surgeon (e.g., cardiothoracic surgeon).
4. Age ≥18 years at time of informed consent signature
5. Adequate vascular access via transfemoral or retroperitoneal approach
6. Informed Consent Form (ICF) signed by the subject or legally authorized representative
7. Agrees to comply with protocol requirements, including imaging and 5-year follow-up
The patient is/has:
1. Ascending and/or Arch Aortic pathologies warranting surgical repair compatible with the treatment requirements of the ASG device and meeting any of the following criteria: Aneurysms
1. Fusiform aneurysm (≥55 mm or documented growth rate \>0.5cm/year)
2. Saccular aneurysm (no diameter criteria)
3. Pseudoaneurysms (\>30 days post-surgery, no diameter criteria) Non-aneurysms
4. Penetrating Aortic Ulcers (no diameter criteria)
5. Pseudoaneurysms, following open surgical repair of a Type A dissection (\>30 days post-surgery, no diameter criteria)
6. Chronic de novo (\>90 days) Type A aortic dissection requiring treatment
* Chronic de novo aortic dissection with primary entry tear in the ascending aorta or arch
* Chronic de novo aortic dissection with primary entry tear in the descending thoracic aorta with retrograde involvement of the aortic arch and/or ascending aorta
7. Residual aortic dissection following surgical repair of Type A aortic dissection requiring treatment (\>30 days post-surgery)
2. Anatomic compatibility with ASG device used in combination with the TBE Device based on Gore Imaging Sciences review.
Proximal Aortic Landing Zone:
1. Landing zone is native aorta or surgical graft
2. Lesion location is ≥2cm distal to the most distal coronary artery ostia
3. Proximal landing zone must be ≥2cm in the ascending aorta.
4. Landing zone cannot be aneurysmal, heavily calcified, or heavily thrombosed
5. Landing zone diameter between 27mm - 48mm
6. Acceptable proximal landing zone outer curvature length for the required device
Branch Vessel Landing Zone:
1. Length of ≥2.5 cm proximal to first major branch vessel
2. Target branch vessel inner diameters of 11-18 mm
3. Target branch vessel landing zone must be in native vessel that cannot be heavily calcified, or heavily thrombosed
Distal Aortic Landing Zone:
1. Outer curvature must be ≥2 cm proximal to the celiac artery
2. Aortic inner diameters between 16-42 mm
3. Landing zone in native aorta or previously implanted GORE® TAG® Conformable Thoracic Stent Graft (CTAG Device)
3. Considered high-risk for open surgical repair by meeting any of the following criteria:
1. ≥75 years of age
2. Previous median sternotomy
3. Documented identification of other subject-specific risk factors (e.g., medical history, active medical diagnosis) by a study investigator and an experienced open ascending and/or aortic arch surgeon (e.g., cardiothoracic surgeon).
4. Age ≥18 years at time of informed consent signature
5. Adequate vascular access via transfemoral or retroperitoneal approach
6. Informed Consent Form (ICF) signed by the subject or legally authorized representative
7. Agrees to comply with protocol requirements, including imaging and 5-year follow-up
Subjects who meet the following criteria will be followed:
1. The aortic lesion involves the ascending aorta and/or aortic arch
2. The subject is determined to be high-risk for open surgical repair per the protocol requirements
3. The subject is at least 18 years of age
4. The subject is willing to comply with the protocol requirements
5. Open surgery to repair the aortic lesion the patient was screened for is intended to be performed at the investigational site responsible for initiating the screening process for the study
Exclusion Criteria
1. De novo Type A dissection
2. Requires immediate treatment
3. Dissected great vessels requiring treatment
4. Anticipated need for coronary or aortic valve intervention within one year post treatment
5. Any aortic valve repair or replacement including transcatheter aortic valve replacement (TAVR) or coronary artery intervention within 30 days prior to treatment
6. Complex percutaneous coronary intervention (PCI) or treatment for acute coronary syndrome requiring Dual Anti Platelet Therapy (DAPT) within 30 days prior to treatment
7. Open chest surgical repair within 30 days prior to treatment
8. Presence of Intramural Hematoma (IMH) in landing zones
9. Prosthetic heart valve in the aortic position that precludes safe delivery of the ASG device
10. Aortic insufficiency grade 3 or greater
11. Previous endovascular repair with a non-Gore device that would interfere with or result in contact with planned repair
12. Concomitant vascular disease requiring treatment that is not planned for index endovascular procedure
13. Any stroke or myocardial infarction within 6 weeks prior to treatment
14. Presence of protruding and/or irregular thrombus and/or atheroma in the ascending aorta or aortic arch or any other factors that could increase the risk of stroke based on imaging review
15. Known degenerative connective tissue disease (e.g., Marfan's or Ehler-Danlos Syndrome, EDS)
16. Participation in investigational drug or medical device study within one year of enrollment unless approved by the sponsor
17. Known history of drug abuse within one year of treatment
18. Pregnant at time of procedure
19. Active infected aorta, mycotic aneurysm
20. Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication)
21. Renal failure, defined as patients with an estimated Glomerular Filtration Rate (eGFR) \<30 (mL/min/1.73 m2) or currently requiring dialysis
22. Life expectancy \<12 months
23. Known sensitivities or allergies to the device materials
24. Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
25. Body habitus or other medical condition which prevents adequate fluoroscopic and CT visualization of the aorta
The patient is/has:
1. Acute and subacute de novo Type A dissection (defined as \<90 days)
2. Requires immediate treatment
3. Dissected great vessels requiring treatment
4. Anticipated need for coronary or aortic valve intervention within one year post treatment
5. Any aortic valve repair or replacement including transcatheter aortic valve replacement (TAVR) or coronary artery intervention within 30 days prior to treatment
6. Complex percutaneous coronary intervention (PCI) or treatment for acute coronary syndrome requiring Dual Anti Platelet Therapy (DAPT) within 30 days prior to treatment.
7. Open chest surgical repair within 30 days prior to treatment
8. Presence of Intramural Hematoma (IMH) in landing zones
9. Prosthetic heart valve in the aortic position that precludes safe delivery of the ASG device
10. Aortic insufficiency grade 3 or greater.
11. Previous endovascular repair with a non-Gore device that would interfere with or result in contact with planned repair
12. Concomitant vascular disease requiring treatment that is not planned for index endovascular procedure
13. Any stroke or myocardial infarction within 6 weeks prior to treatment
14. Presence of protruding and/or irregular thrombus and/or atheroma in the ascending aorta or aortic arch or any other factors that could increase the risk of stroke based on imaging review
15. Known degenerative connective tissue disease (e.g., Marfan Syndrome or Ehlers-Danlos Syndrome, EDS)
16. Participation in investigational drug or medical device study within one year of enrollment unless approved by the sponsor
17. Known history of drug abuse within one year of treatment
18. Pregnant at time of procedure
19. Active infected aorta, mycotic aneurysm
20. Active systemic infection (e.g., infection requiring treatment with parenteral anti-infective medication)
21. Renal failure, defined as patients with an estimated Glomerular Filtration Rate (eGFR) \<30 (mL/min/1.73 m2) or currently requiring dialysis
22. Life expectancy \<12 months
23. Known sensitivities or allergies to the device materials
24. Known hypersensitivity or contraindication to anticoagulants or contrast media, which is not amenable to pre-treatment
25. Body habitus or other medical condition which prevents adequate fluoroscopic and CT visualization of the aorta
26. Previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or known hypersensitivity to heparin or a history of a hypercoagulability disorder and/or state
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
W.L.Gore & Associates
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eric Roselli, MD
Role: PRINCIPAL_INVESTIGATOR
The Cleveland Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
MemorialCare Heart and Vascular Institute - Long Beach Medical Center
Long Beach, California, United States
Keck Medical Center University of Southern California, HCC II
Los Angeles, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Stanford Hospital
Stanford, California, United States
University of Colorado Hospital Authority
Aurora, Colorado, United States
Hartford Hospital
Hartford, Connecticut, United States
MedStar Washington Hospital Center
Washington D.C., District of Columbia, United States
University of Florida - Gainesville
Gainesville, Florida, United States
Emory University Hospital
Atlanta, Georgia, United States
Northwestern University -Bluhm Cardiovascular Institute, Clinical Trials Unit
Chicago, Illinois, United States
Indiana University School of Medicine
Indianapolis, Indiana, United States
University of Maryland Medical Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
University of Michigan Frankel Cardiovascular Center
Ann Arbor, Michigan, United States
Corewell Health
Grand Rapids, Michigan, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Washington University School of Medicine - St. Louis
St Louis, Missouri, United States
Hackensack UMC
Hackensack, New Jersey, United States
Westchester Medical Center
Valhalla, New York, United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Atrium Health
Charlotte, North Carolina, United States
Duke University Medical Center
Durham, North Carolina, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
OhioHealth Research and Innovation Institute
Columbus, Ohio, United States
Oregon Health and Science University
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Cardiothoracic and Vascular Surgeons
Austin, Texas, United States
Methodist DeBakey Heart & Vascular Center
Houston, Texas, United States
The Heart Hospital at Baylor Plano
Plano, Texas, United States
Intermountain Heart Institute
Murray, Utah, United States
Inova Fairfax Medical Campus
Falls Church, Virginia, United States
Sentara Mid Atlantic Cardiothoracic Surgeons
Norfolk, Virginia, United States
University of Washington Medical Center
Seattle, Washington, United States
West Virginia University Medicine
Morgantown, West Virginia, United States
University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ASG 22-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.